Literature DB >> 18202696

Diagnosing and exploiting cancer's addiction to blocks in apoptosis.

Anthony G Letai1.   

Abstract

Cancer cells survive despite violating rules of normal cellular behaviour that ordinarily provoke apoptosis. The blocks in apoptosis that keep cancer cells alive are therefore attractive candidates for targeted therapies. Recent studies have significantly increased our understanding of how interactions among proteins in the BCL2 family determine cell survival or death. It is now possible to systematically determine how individual cancers escape apoptosis. Such a determination can help predict not only whether cells are likely to be killed by antagonism of BCL2, but also whether they are likely to be sensitive to chemotherapy that kills by the intrinsic apoptotic pathway.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18202696     DOI: 10.1038/nrc2297

Source DB:  PubMed          Journal:  Nat Rev Cancer        ISSN: 1474-175X            Impact factor:   60.716


  253 in total

1.  Discovery and prioritization of somatic mutations in diffuse large B-cell lymphoma (DLBCL) by whole-exome sequencing.

Authors:  Jens G Lohr; Petar Stojanov; Michael S Lawrence; Daniel Auclair; Bjoern Chapuy; Carrie Sougnez; Peter Cruz-Gordillo; Birgit Knoechel; Yan W Asmann; Susan L Slager; Anne J Novak; Ahmet Dogan; Stephen M Ansell; Brian K Link; Lihua Zou; Joshua Gould; Gordon Saksena; Nicolas Stransky; Claudia Rangel-Escareño; Juan Carlos Fernandez-Lopez; Alfredo Hidalgo-Miranda; Jorge Melendez-Zajgla; Enrique Hernández-Lemus; Angela Schwarz-Cruz y Celis; Ivan Imaz-Rosshandler; Akinyemi I Ojesina; Joonil Jung; Chandra S Pedamallu; Eric S Lander; Thomas M Habermann; James R Cerhan; Margaret A Shipp; Gad Getz; Todd R Golub
Journal:  Proc Natl Acad Sci U S A       Date:  2012-02-17       Impact factor: 11.205

2.  BCL2 suppresses PARP1 function and nonapoptotic cell death.

Authors:  Chaitali Dutta; Tovah Day; Nadja Kopp; Diederik van Bodegom; Matthew S Davids; Jeremy Ryan; Liat Bird; Naveen Kommajosyula; Oliver Weigert; Akinori Yoda; Hua Fung; Jennifer R Brown; Geoffrey I Shapiro; Anthony Letai; David M Weinstock
Journal:  Cancer Res       Date:  2012-06-11       Impact factor: 12.701

3.  Bcl-2 and Bax interact via the BH1-3 groove-BH3 motif interface and a novel interface involving the BH4 motif.

Authors:  Jingzhen Ding; Zhi Zhang; G Jane Roberts; Mina Falcone; Yiwei Miao; Yuanlong Shao; Xuejun C Zhang; David W Andrews; Jialing Lin
Journal:  J Biol Chem       Date:  2010-06-28       Impact factor: 5.157

4.  Bax activation by engagement with, then release from, the BH3 binding site of Bcl-xL.

Authors:  F Gautier; Y Guillemin; P F Cartron; T Gallenne; N Cauquil; T Le Diguarher; P Casara; F M Vallette; S Manon; J A Hickman; O Geneste; P Juin
Journal:  Mol Cell Biol       Date:  2010-12-20       Impact factor: 4.272

Review 5.  EGFR(S) inhibitors in the treatment of gastro-intestinal cancers: what's new?

Authors:  Shailender Singh Kanwar; Jyoti Nautiyal; Adhip P N Majumdar
Journal:  Curr Drug Targets       Date:  2010-06       Impact factor: 3.465

6.  Mechanism of action of SNS-032, a novel cyclin-dependent kinase inhibitor, in chronic lymphocytic leukemia.

Authors:  Rong Chen; William G Wierda; Sherri Chubb; Rachael E Hawtin; Judith A Fox; Michael J Keating; Varsha Gandhi; William Plunkett
Journal:  Blood       Date:  2009-02-20       Impact factor: 22.113

7.  Cleavage of Bid by executioner caspases mediates feed forward amplification of mitochondrial outer membrane permeabilization during genotoxic stress-induced apoptosis in Jurkat cells.

Authors:  Shary N Shelton; Mary E Shawgo; John D Robertson
Journal:  J Biol Chem       Date:  2009-02-19       Impact factor: 5.157

8.  Antioxidant activity of growth hormone-releasing hormone antagonists in LNCaP human prostate cancer line.

Authors:  Nektarios Barabutis; Andrew V Schally
Journal:  Proc Natl Acad Sci U S A       Date:  2008-12-15       Impact factor: 11.205

9.  Molecular analysis of functional redundancy among anti-apoptotic Bcl-2 proteins and its role in cancer cell survival.

Authors:  Joshua M Eichhorn; Sarah E Alford; Nandini Sakurikar; Timothy C Chambers
Journal:  Exp Cell Res       Date:  2014-02-17       Impact factor: 3.905

10.  BH3 profiling discriminates response to cytarabine-based treatment of acute myelogenous leukemia.

Authors:  William E Pierceall; Steven M Kornblau; Nicole E Carlson; Xuelin Huang; Noel Blake; Ryan Lena; Michael Elashoff; Marina Konopleva; Michael H Cardone; Michael Andreeff
Journal:  Mol Cancer Ther       Date:  2013-10-03       Impact factor: 6.261

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.